Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pacira BioSciences, Inc. (NASDAQ: PCRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Pacira is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its filings give detailed insight into how it manages product commercialization, manufacturing, financing and governance.
Pacira’s current reports on Form 8‑K cover topics such as quarterly financial results, workforce reductions tied to manufacturing efficiencies for EXPAREL, and a senior secured revolving credit facility used to refinance prior indebtedness and support working capital. One 8‑K describes the company’s investment in large-scale manufacturing suites in San Diego, California, and Swindon, United Kingdom, and the decision to decommission an earlier 45‑liter batch suite, while another outlines the terms of its credit agreement with lenders.
Investors reviewing Pacira’s filings typically focus on annual reports on Form 10‑K and quarterly reports on Form 10‑Q for information about its commercial products—EXPAREL, ZILRETTA and iovera°—and its clinical-stage gene therapy candidate PCRX-201. These filings generally discuss revenue composition, research and development activities, manufacturing capacity, risk factors and intellectual property, including patent protection for EXPAREL described in company press releases.
Forms 8‑K also document material events such as share repurchase authorizations, inducement equity grants under the company’s inducement plan, credit facility amendments and other significant corporate actions. For users interested in insider activity, Forms 3, 4 and 5 provide data on transactions by directors, officers and major shareholders, while proxy statements explain executive compensation and board matters.
On Stock Titan, AI-generated summaries help explain lengthy filings, highlight key changes from prior periods and surface items that may affect Pacira’s financial position or strategy. Real-time updates from EDGAR ensure that new 10‑K, 10‑Q, 8‑K and Form 4 filings for PCRX are quickly available, allowing investors to track developments in Pacira’s non-opioid pain portfolio, manufacturing initiatives and capital structure without reading every page manually.
Pacira BioSciences, Inc. CEO Lee Frank D. reported an automatic share withholding related to equity compensation. On January 30, 2026, 41,488 shares of common stock were withheld by Pacira at $20.54 per share to cover tax obligations on a vested restricted stock unit award.
After this tax withholding, Lee Frank D. directly beneficially owned 399,012.841 shares of Pacira common stock. The transaction reflects routine administration of equity compensation rather than an open-market trade.
Pacira BioSciences shareholder plans a modest stock sale under Rule 144. A holder filed to sell 4,000 shares of Pacira common stock on NASDAQ through Fidelity Brokerage Services LLC, with an indicated aggregate market value of $84,219.34.
The shares were acquired on 02/01/2026 through restricted stock vesting from the issuer as compensation, with payment recorded the same day. The notice also discloses that the same person sold 1,416 common shares on 01/05/2026 for gross proceeds of $34,323.84. Common shares outstanding for this class are listed as 43,021,275.
A holder of PCRX common stock filed a notice to sell 13,137 shares under Rule 144. The shares are common stock to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/02/2026 and aggregate market value of 269,702.61.
The securities were acquired as restricted stock vesting from the issuer on 02/01/2026, treated as compensation. The filing notes that there were 43,021,275 shares of this class outstanding at the time, providing baseline context for the planned sale size.
Pacira BioSciences, Inc. director Samit Hirawat received a grant of stock options on January 27, 2026. The award covers 39,291 stock options with an exercise price of $19.85 per share, held directly, and represents a right to buy common stock.
According to the vesting terms, one-third of the options vest on the first anniversary of the grant date. The remaining options vest in equal monthly installments over the following two years, as long as the director continues in service. The options expire on January 27, 2036.
Pacira BioSciences, Inc. director Samit Hirawat filed an initial ownership report on Form 3. The filing states that, as of the event date of 01/27/2026, no securities of Pacira BioSciences are beneficially owned. This is an administrative disclosure of current holdings status.
Pacira BioSciences, Inc. expanded its Board of Directors from nine to ten members and appointed Dr. Samit Hirawat as a Class III director, effective immediately on January 27, 2026. He will also serve on the Board’s Science and Technology Committee.
Dr. Hirawat will receive Pacira’s standard compensation for non-employee directors. The Board determined that he qualifies as an independent director under Nasdaq’s listing standards. The company later issued a press release on January 28, 2026 to publicly announce his appointment.
DOMA Perpetual Capital Management LLC, which says it beneficially owns approximately 6.83% of Pacira BioSciences, Inc. common stock, plans to run a dissident slate of three independent director candidates at Pacira’s 2026 annual shareholder meeting. DOMA states that Pacira’s board should pursue an immediate sale of the company and criticizes current executive compensation and general spending as “exorbitant and unmerited,” while also questioning whether the board has provided appropriate fiduciary oversight.
DOMA and affiliated entities, including DOMA Perpetual LO Equity Master Fund LP, DOMA Perpetual Partners GP LLC, Reliability LLC and Pedro Escudero, intend to solicit votes using a WHITE proxy card and will file a detailed proxy statement with the SEC. The group collectively may be deemed to beneficially own several million Pacira shares through various entities, and it urges Pacira stockholders to review its forthcoming proxy materials when available.
Pacira BioSciences, Inc. filed a current report stating that it has issued a press release with its preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company is sharing an early view of its 2025 revenue performance before final audited results are available.
The press release, dated January 8, 2026, is included as Exhibit 99.1. Pacira notes that this revenue information is being furnished rather than filed under securities laws, which limits how it is treated for certain liability and incorporation-by-reference purposes.
Pacira BioSciences Chief Medical Officer Jonathan Slonin reported an automatic share withholding related to equity compensation. On January 2, 2026, 381 shares of Pacira common stock were withheld at $24.46 per share to cover tax obligations when a restricted stock unit award vested. After this withholding, Slonin beneficially owned 178,523.175 shares of Pacira common stock, which includes 537.166 shares acquired through the company’s employee stock purchase plan in December 2025. This filing reflects routine tax and ownership reporting rather than an open-market trade.
Pacira BioSciences Senior Vice President of Finance Lauren Riker reported two stock transactions in early January 2026. On January 2, 2026, 159 shares of Pacira common stock were withheld by the company at $24.46 per share to cover tax obligations when a restricted stock unit award vested. On January 5, 2026, Riker sold 1,416 shares of common stock at a price of $24.24 per share under a pre‑established Rule 10b5‑1 trading plan. After these transactions, Riker directly owned 59,064.242 shares of Pacira common stock, which includes 1,075.242 shares acquired through the company’s employee stock purchase plan in December 2025.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
